Precigen (NASDAQ:PGEN) Reaches New 52-Week High – Here’s Why

Precigen, Inc. (NASDAQ:PGEN) shares reached a new 52-week high on Thursday . The stock traded as high as $7.23 and last traded at $6.89, with a volume of 16909114 shares traded. The stock had previously closed at $6.53.

More Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 earnings beat: Precigen reported $54.98 million in revenue, far above the roughly $28 million analyst consensus, while earnings were $0.05 per share versus expectations for a loss of approximately $0.01–$0.02. Revenue increased sharply year over year, and the company posted $20.1 million in net income attributable to common shareholders. Precigen Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: PAPZIMEOS momentum is driving the business: PAPZIMEOS generated $53.1 million of Q2 net revenue, more than double the prior quarter. Patient-hub enrollment exceeded 500, and FDA-granted seven-year market exclusivity strengthens the product’s commercial outlook. Management said current resources and product revenue are expected to support cash-flow break-even by the end of 2026. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: HC Wainwright reiterated its Buy rating and $14 price target, well above recent trading levels. The firm’s endorsement reinforced the bullish reaction to the earnings report. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually heavy options activity suggests increased investor attention and potentially higher near-term volatility, but the report does not establish whether options traders are primarily bullish or bearish. Precigen Target of Unusually Large Options Trading
• Negative Sentiment: Insider selling is a counterpoint: Precigen executives, including the COO, CEO and CFO, have reported stock sales, with no insider purchases cited over the past six months. The latest COO sale was made under a pre-arranged Rule 10b5-1 plan, reducing its informational significance but still presenting a potential overhang. Precigen Insider Selling

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PGEN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. HC Wainwright raised their target price on Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Finally, Citizens Jmp upped their price target on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.50.

Precigen Stock Performance

The company has a quick ratio of 4.12, a current ratio of 4.82 and a debt-to-equity ratio of 4.62. The business has a 50 day moving average price of $5.12 and a two-hundred day moving average price of $4.46. The stock has a market cap of $2.46 billion, a P/E ratio of -6.62 and a beta of 1.02.

Precigen (NASDAQ:PGEN) last issued its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 484.64% and a negative net margin of 183.98%.The company had revenue of $54.98 million for the quarter, compared to the consensus estimate of $27.98 million. The business’s revenue for the quarter was up 6322.7% compared to the same quarter last year. On average, sell-side analysts forecast that Precigen, Inc. will post -0.02 earnings per share for the current fiscal year.

Insider Activity at Precigen

In other news, CFO Harry Jr. Thomasian sold 100,000 shares of Precigen stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $6.06, for a total transaction of $606,000.00. Following the sale, the chief financial officer owned 254,535 shares in the company, valued at $1,542,482.10. This trade represents a 28.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 33,772 shares of Precigen stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $6.50, for a total transaction of $219,518.00. Following the sale, the chief operating officer owned 497,751 shares in the company, valued at approximately $3,235,381.50. The trade was a 6.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 956,500 shares of company stock valued at $5,248,371. Corporate insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Occam Crest Management LP lifted its stake in Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock worth $14,637,000 after purchasing an additional 799,339 shares in the last quarter. KBC Group NV bought a new position in shares of Precigen during the 1st quarter valued at about $1,338,000. UBS Group AG grew its position in shares of Precigen by 41.4% during the fourth quarter. UBS Group AG now owns 891,428 shares of the biotechnology company’s stock valued at $3,726,000 after purchasing an additional 260,824 shares in the last quarter. Investment Insight Wealth Management LLC purchased a new position in shares of Precigen during the fourth quarter valued at about $443,000. Finally, Impala Asset Management LLC bought a new stake in shares of Precigen in the fourth quarter worth about $690,000. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.